Anti-fungal therapy at the HAART of viral therapy

Trends in Microbiology

Volumn 10, Issue 4, 2002, Pages 173-177

  Munro, Carol A ^a   Hube, Bernhard ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; FUNGAL ENZYME; INDINAVIR; PEPSTATIN; PROTEIN PRECURSOR; PROTEINASE; PROTEINASE INHIBITOR; RENIN INHIBITOR; RITONAVIR; SAQUINAVIR; VIRULENCE FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CANDIDIASIS; COMBINATION CHEMOTHERAPY; CROSS REACTION; DRUG TARGETING; ENZYME RELEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUTH INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; VAGINA CANDIDIASIS; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTIC ENDOPEPTIDASES; CANDIDA; CANDIDIASIS, ORAL; FUNGAL PROTEINS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; VIRULENCE;

CANDIDA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0036532398     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(02)02330-2     Document Type: Review

References (42)

1. Relationship between fluconazole sensitivity of Candida albicans isolates from HIV positive patients and serotype, adherence and CD4+ lymphocyte count
2. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir
3. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: A 2-year study
4. Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor
5. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: A prospective case-control study
6. The structure and function of the aspartic proteinases
7. Pepstatin, a new pepsin inhibitor produced by Actinomycetes
8. Evolution in the structure and function of aspartic proteases
9. Targeting the HIV-protease in AIDS therapy: A current clinical perspective
10. Active human immunodeficiency virus protease is required for viral infectivity
11. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1
12. Retroviral proteinases. A second front against AIDS
13. Development of drug resistance to HIV-1 protease inhibitors
14. Sequence of the Candida albicans gene encoding the secretory aspartate proteinase
15. A second gene for a secreted aspartate proteinase in Candida albicans
16. Three distinct secreted aspartyl proteinases in Candida albicans
17. Multiplicity of genes encoding secreted aspartic proteinases in Candida species
18. Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans
19. Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence
20. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence
21. Possible role of proteinases in Candida infections
22. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients
23. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus
24. High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women
25. Differential activation of a Candida albicans virulence gene family during infection
26. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis
27. In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients
28. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis
29. Modulation of experimental systemic murine candidosis by intravenous pepstatin
30. Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes
31. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats
32. Role of aspartic proteases in disseminated Candida albicans infection in mice
33. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro
34. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors
35. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients
36. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors
37. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors
38. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases
39. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro
40. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii
41. Candida species and virulence
42. Virulence factors of Candida albicans